Cargando…

Cardiovascular Events in Cancer Patients Treated with Highly or Moderately Emetogenic Chemotherapy: Results from a Population-Based Study

Studies on cardiovascular safety in cancer patients treated with highly or moderately emetogenic chemotherapy (HEC or MEC), who may have taken the antiemetic, aprepitant, have been limited to clinical trials and postmarketing spontaneous reports. Our study explored background rates of cardiovascular...

Descripción completa

Detalles Bibliográficos
Autores principales: Vo, Thao T., Nelson, Jeanenne J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335187/
https://www.ncbi.nlm.nih.gov/pubmed/22570656
http://dx.doi.org/10.1155/2012/529357
_version_ 1782230763139235840
author Vo, Thao T.
Nelson, Jeanenne J.
author_facet Vo, Thao T.
Nelson, Jeanenne J.
author_sort Vo, Thao T.
collection PubMed
description Studies on cardiovascular safety in cancer patients treated with highly or moderately emetogenic chemotherapy (HEC or MEC), who may have taken the antiemetic, aprepitant, have been limited to clinical trials and postmarketing spontaneous reports. Our study explored background rates of cardiovascular disease (CVD) events among HEC- or MEC-treated cancer patients in a population-based setting to contextualize events seen in a new drug development program and to determine at a high level whether rates differed by aprepitant usage. Medical and pharmacy claims data from the 2005–2007 IMPACT National Benchmark Database were classified into emetogenic chemotherapy categories and CVD outcomes. Among 5827 HEC/MEC-treated patients, frequencies were highest for hypertension (16–21%) and composites of venous (7–12%) and arterial thromboembolic events (4–7%). Aprepitant users generally did not experience higher frequencies of events compared to nonusers. Our study serves as a useful benchmark of background CVD event rates in a population-based setting of cancer patients.
format Online
Article
Text
id pubmed-3335187
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-33351872012-05-08 Cardiovascular Events in Cancer Patients Treated with Highly or Moderately Emetogenic Chemotherapy: Results from a Population-Based Study Vo, Thao T. Nelson, Jeanenne J. J Cancer Epidemiol Research Article Studies on cardiovascular safety in cancer patients treated with highly or moderately emetogenic chemotherapy (HEC or MEC), who may have taken the antiemetic, aprepitant, have been limited to clinical trials and postmarketing spontaneous reports. Our study explored background rates of cardiovascular disease (CVD) events among HEC- or MEC-treated cancer patients in a population-based setting to contextualize events seen in a new drug development program and to determine at a high level whether rates differed by aprepitant usage. Medical and pharmacy claims data from the 2005–2007 IMPACT National Benchmark Database were classified into emetogenic chemotherapy categories and CVD outcomes. Among 5827 HEC/MEC-treated patients, frequencies were highest for hypertension (16–21%) and composites of venous (7–12%) and arterial thromboembolic events (4–7%). Aprepitant users generally did not experience higher frequencies of events compared to nonusers. Our study serves as a useful benchmark of background CVD event rates in a population-based setting of cancer patients. Hindawi Publishing Corporation 2012 2012-04-12 /pmc/articles/PMC3335187/ /pubmed/22570656 http://dx.doi.org/10.1155/2012/529357 Text en Copyright © 2012 T. T. Vo and J. J. Nelson. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Vo, Thao T.
Nelson, Jeanenne J.
Cardiovascular Events in Cancer Patients Treated with Highly or Moderately Emetogenic Chemotherapy: Results from a Population-Based Study
title Cardiovascular Events in Cancer Patients Treated with Highly or Moderately Emetogenic Chemotherapy: Results from a Population-Based Study
title_full Cardiovascular Events in Cancer Patients Treated with Highly or Moderately Emetogenic Chemotherapy: Results from a Population-Based Study
title_fullStr Cardiovascular Events in Cancer Patients Treated with Highly or Moderately Emetogenic Chemotherapy: Results from a Population-Based Study
title_full_unstemmed Cardiovascular Events in Cancer Patients Treated with Highly or Moderately Emetogenic Chemotherapy: Results from a Population-Based Study
title_short Cardiovascular Events in Cancer Patients Treated with Highly or Moderately Emetogenic Chemotherapy: Results from a Population-Based Study
title_sort cardiovascular events in cancer patients treated with highly or moderately emetogenic chemotherapy: results from a population-based study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335187/
https://www.ncbi.nlm.nih.gov/pubmed/22570656
http://dx.doi.org/10.1155/2012/529357
work_keys_str_mv AT vothaot cardiovasculareventsincancerpatientstreatedwithhighlyormoderatelyemetogenicchemotherapyresultsfromapopulationbasedstudy
AT nelsonjeanennej cardiovasculareventsincancerpatientstreatedwithhighlyormoderatelyemetogenicchemotherapyresultsfromapopulationbasedstudy